{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:07:13Z","timestamp":1791450433426,"version":"4.3.3"},"reference-count":10,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2025,7,17]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Optic neuritis is a rare immune-related adverse event of immune checkpoint inhibitor use and may result in poor visual outcomes. We describe an elderly woman with metastatic malignant melanoma treated with nivolumab, a programmed cell death protein 1 immune checkpoint inhibitor. After 2 months, she developed bilateral painless loss of vision due to optic neuritis. Although there is limited evidence, expert opinion favours early corticosteroid use and\/or plasma exchange, as recommended for neuromyelitis optica spectrum disorders. Optic neuritis is increasingly recognised as an immune-related adverse event, likely to occur more frequently with greater use of immune checkpoint inhibitors. Its early recognition is important as prompt treatment can improve outcomes.<\/jats:p>","DOI":"10.1136\/pn-2025-004640","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:45:17Z","timestamp":1753940717000},"page":"246-250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitor-associated bilateral optic neuritis"],"prefix":"10.1136","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-7567","authenticated-orcid":false,"given":"Chris","family":"Gyan","sequence":"first","affiliation":[{"name":"Department of Neurology, Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-7442","authenticated-orcid":false,"given":"Maria","family":"Bonello","sequence":"additional","affiliation":[{"name":"Neurosciences, Mater Dei Hospital, Msida, Malta, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-9600","authenticated-orcid":false,"given":"Ashwin Arnold","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2026051402150815000_26.3.246.1","doi-asserted-by":"crossref","first-page":"774170","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026051402150815000_26.3.246.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"2026051402150815000_26.3.246.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"2026051402150815000_26.3.246.4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic Adverse Events of Immune Checkpoint Inhibitors","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2026051402150815000_26.3.246.5","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004327"},{"key":"2026051402150815000_26.3.246.6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000491075","article-title":"Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma","volume":"9","author":"Mori","year":"2018","journal-title":"Case Rep Ophthalmol"},{"key":"2026051402150815000_26.3.246.7","first-page":"e866","article-title":"Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2026051402150815000_26.3.246.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026051402150815000_26.3.246.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026051402150815000_26.3.246.10","doi-asserted-by":"crossref","first-page":"1171981","DOI":"10.3389\/fimmu.2023.1171981","article-title":"Pembrolizumab-induced optic neuropathy - a case report","volume":"14","author":"Daetwyler","year":"2023","journal-title":"Front Immunol"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2025-004640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:16:08Z","timestamp":1778750168000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2025-004640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/pn-2025-004640"],"URL":"https:\/\/doi.org\/10.1136\/pn-2025-004640","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}